Clinical Trials
162 trialsAMYLOCARP
Ramsay Générale de Santé
Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
Beijing Boren Hospital
MGUS-PET
University of Zurich
A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
Stanford University
Towards Effective, Patient-tailored Anti-plasma Cell Therapies in AL Amyloidosis: Predicting Drug Response and Overcoming Drug Resistance
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
University of Texas Southwestern Medical Center
ALPS
Fondazione IRCCS Policlinico San Matteo di Pavia
BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy
Institute of Hematology & Blood Diseases Hospital, China
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
Case Comprehensive Cancer Center
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia
ReAL
Fondazione IRCCS Policlinico San Matteo di Pavia
EUREKA
Fondazione IRCCS Policlinico San Matteo di Pavia
ProDigALIty
Fondazione IRCCS Policlinico San Matteo di Pavia
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Mayo Clinic
ITA-WebNet
Fondazione IRCCS Policlinico San Matteo di Pavia
B-SCR-MM
Ohio State University Comprehensive Cancer Center
MED-hATTR
The Cleveland Clinic
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Peking University People's Hospital
Rapid dFLC Response Predict CHR in AL Amyloidosis
Peking University People's Hospital
BMT
Massachusetts General Hospital
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Brigham and Women's Hospital
GlycAL
Fondazione IRCCS Policlinico San Matteo di Pavia
Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
M.D. Anderson Cancer Center
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Weill Medical College of Cornell University
BE.Amycon Biobank & Data Registry UZ Leuven
Universitaire Ziekenhuizen KU Leuven
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Emory University
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
City of Hope Medical Center
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
Peking University People's Hospital
Ixazomib Maintenance Study in Patients With AL Amyloidosis
Memorial Sloan Kettering Cancer Center
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Boston Medical Center
Teclistamab-Daratumumab in AL Amyloidosis
Columbia University
MICA
Brigham and Women's Hospital
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Memorial Sloan Kettering Cancer Center
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
Peking University First Hospital
EAR
University Hospital, Essen
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Tufts Medical Center
AL-CA
Beijing Anzhen Hospital
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
Peking Union Medical College Hospital
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Columbia University
Registry of Older Patients With Cancer
UNC Lineberger Comprehensive Cancer Center
Teclistamab in Previously Treated AL Amyloidosis
Peking Union Medical College Hospital
Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis
Beijing Boren Hospital
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Hadassah Medical Organization
Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis
Peking University People's Hospital
ICAR
Leiden University Medical Center
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
University of California, San Francisco
NIMMS
St. Olavs Hospital
DarPAL
Fondazione IRCCS Policlinico San Matteo di Pavia